The scientific community is one of the few human enterprises that refuses to require a passport. A discovery made in a lab in Copenhagen or Cambridge or Kyoto belongs to anyone with the training to read the paper and the resources to act on it. We celebrate this when it suits us. The mRNA platform pioneered by a Hungarian biochemist working in Pennsylvania. The CRISPR techniques refined across continents. The structural biology that emerged from a British lab and now informs drug design everywhere. The community of medicine, when it does science, behaves like a community.
The community of medicine, when it delivers care, behaves like nothing of the sort.
This is the contradiction that deserves more honest examination than the profession has been willing to give it. We are trained to think of ourselves as scientists. We cite evidence, we read trials, we revise our practice when the data demand it. And yet on the question of how that practice actually reaches patients, who can afford it, who is excluded, what it costs, and why, most of us have been remarkably incurious. We treat the delivery system as someone else’s problem. It isn’t.
Take semaglutide, the molecule sold here as Ozempic and Wegovy. It was developed in Denmark, building on decades of work by Danish scientists, and American physicians adopted it quickly because the science is genuinely transformative. The science crossed the Atlantic without friction. The price did not. The same drug, made by the same company, costs roughly $1,000 a month in the United States and about $122 in Denmark. The molecule does not care which country the patient is standing in. The pricing structure does, and it is not a scientific structure. It is a legislative one.
This is where I think medicine has failed its own standards. We are quick to demand evidence for a new therapy and slow to demand evidence for the system that delivers it. We will scrutinize a p value to three decimal places and shrug at the fact that a patient in our waiting room is rationing insulin or splitting injection pens because her copay is untenable. We treat the financial architecture of American healthcare as though it were weather, a thing that happens to us rather than a thing we participate in and could, if we chose, push against.
The defense usually offered is that this is not our lane. We are clinicians, not policy analysts. But that defense collapses the moment you take seriously what it means to treat a population. Public health is not an add on to medicine. It is medicine practiced at scale. If a drug works in a trial of 10,000 people but is unaffordable to 200 million, the population level effect of that drug is approximately zero. The science has done its job. The delivery system has nullified it. A profession that calls itself scientific should find this intolerable, and should say so out loud, frequently, in the venues where it might matter.
There is a deeper irony here. The randomized trials that established semaglutide’s efficacy enrolled patients across dozens of countries, and we accept those results as universally applicable, because biology is universal. But the moment that universal biology meets the American regulatory and commercial framework, we accept, with a kind of trained helplessness, that access becomes a function of zip code, employer, and insurance tier. We have allowed a non-scientific variable to become the dominant determinant of whether scientific progress reaches the patient.
What I want from my profession, and from myself, is a more critical posture toward the system we work inside. Not a partisan posture. This is not a left or right issue, and framing it that way has been one of the more effective ways to keep it unresolved. It is a scientific posture. If we believe medicine is a scientific community, then we should be embarrassed that the delivery of its products is governed by a framework no scientist designed and few of us have seriously interrogated. Science crosses borders effortlessly. The benefits of science should not have to wait for an act of Congress.